# MT-302

Source: https://onco.cc/drugs/mt-302/  
OnCo record `mt-302` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MT-302 programs myeloid immune cells inside the body to recognise TROP-2-bearing cancers. It is an experimental treatment in an early clinical trial.

## Summary

The 2025 ASCO correlative abstract describes intravenous mRNA-LNP delivery of an anti-TROP2 scFv/truncated-CD89 CAR, functionally active upon association with FcRgamma-expressing myeloid cells. It reports tumour and blood pharmacodynamic observations, not a comparative efficacy estimate. NCT05969041 remains recruiting in its last registry update, dated January 2024; planned enrolment is 48. The registry age does not establish current local slot availability.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-10-06
- Modality: In vivo myeloid cell therapy (mRNA lipid nanoparticles)
- Mechanism: mRNA lipid nanoparticles encode an anti-TROP2 CAR to engage FcRgamma-expressing myeloid cells in vivo.

## Sources

- ClinicalTrials.gov NCT05969041: https://clinicaltrials.gov/study/NCT05969041
- Primary correlative abstract: https://doi.org/10.1200/JCO.2025.43.16_suppl.2591

## Connected records

- targets: [TROP2](https://onco.cc/targets/trop2/)
- trials: [Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors](https://onco.cc/trials/nct05969041/)

---
JSON: https://onco.cc/api/v1/entities/mt-302.json